Amyotrophic lateral sclerosis

The ALS Association Launches PSA Campaign Showing 'The Reality of ALS'

Retrieved on: 
Tuesday, May 8, 2018
Amyotrophic lateral sclerosis, Neurology, Health, Medicine, ALS Awareness Month, ALS Association, Public service announcement

WASHINGTON, May 8, 2018 /PRNewswire-USNewswire/ --The ALS Association has released a series of public service announcements (PSAs) highlighting what life is like with ALS.

Key Points: 
  • WASHINGTON, May 8, 2018 /PRNewswire-USNewswire/ --The ALS Association has released a series of public service announcements (PSAs) highlighting what life is like with ALS.
  • Throughout May, which is ALS Awareness Month, the Association will promote and distribute three separate PSAs showing "The Reality of ALS."
  • "Many people have heard of ALS, but they may not know much about the disease," said Brian Frederick, executive vice president of communications of The ALS Association.
  • "Our goal with this PSA campaign is to show what it's like to live with ALS and the devastating impact the disease has on families.

Benitec to Host Investor Webinar on the Company's Oculopharyngeal Muscular Dystrophy (OPMD) Program

Retrieved on: 
Thursday, May 3, 2018
RTT, Rare diseases, Medicine, Clinical medicine, Dysphagia, Oculopharyngeal muscular dystrophy, Aspiration pneumonia, Pneumonia, Amyotrophic lateral sclerosis

Benitec Biopharma is based in Sydney, Australia with laboratories in Hayward, California (USA).

Key Points: 
  • Benitec Biopharma is based in Sydney, Australia with laboratories in Hayward, California (USA).
  • Progressing throughout that patient's life, OPMD is not typically diagnosed until the individuals reach their late 40s.
  • As the dysphagia becomes more severe, patients become malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia.
  • Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

MDA And ALS ONE Form New Partnership To Accelerate ALS Biomarker Research

Retrieved on: 
Friday, May 4, 2018
Amyotrophic lateral sclerosis, Neurology, ALS Therapy Development Institute, Nervous system, Jamie Heywood, Sean F. Scott

This important grant was catalyzed by ALS ONE, a partnership between four institutional leaders in ALS treatment development: Massachusetts General Hospital (MGH), ALS Therapy Development Institute (ALS TDI), University of Massachusetts Medical School and Compassionate Care ALS (CCALS).

Key Points: 
  • This important grant was catalyzed by ALS ONE, a partnership between four institutional leaders in ALS treatment development: Massachusetts General Hospital (MGH), ALS Therapy Development Institute (ALS TDI), University of Massachusetts Medical School and Compassionate Care ALS (CCALS).
  • The ALS ONE partnership was developed to expedite treatments for ALS and develop novel approaches to improve care for those living with the disease.
  • Ultimately, this biomarker will be available for any researcher or pharmaceutical company to use for drug development in ALS.
  • Gosnell passed away in August 2016 due to complications from ALS, following his final meeting at which he spoke with MDA about partnership opportunities.